Stock listing
NASDAQ:ANAB AnaptysBio, Inc. Stock
Home listing (NASDAQ) of AnaptysBio, Inc.
Follow AnaptysBio, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ANAB
$46.63 USD -0.43 (-0.9%)
Close on Nov 20, 2026
- Day range
- $46.05 – $47.66 USDNov 20, 2026
- Volume
- 432,444 sharesNov 20, 2026
- Market cap
- $1.39B USDAt the close on Nov 20, 2026 · price × 29.90M shares outstanding
- 52-week range
- $22.07 – $72.36 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $25.00M USDMedian day 421,700 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ANAB · Home | $46.63 USD | -0.43 (-0.9%) | 432,444 | $46.63 | $47.66 | $46.05 | $47.06 | Close on Nov 20, 2026 |
| LSE:0HFQ | $46.91 USD | -0.889 (-1.9%) | 850 | $45.76 | $47.32 | $45.76 | $47.80 | Close on Nov 20, 2026 |
| Frankfurt:AN6 | €41.93 EUR | -0.16 (-0.4%) | — | €42.31 | €42.44 | €41.32 | €42.09 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ANAB · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $46.63 | -0.43 | -0.9% | $46.63 | $47.66 | $46.05 | 432,444 | |
| $47.06 | +1.45 | +3.2% | $45.59 | $47.18 | $44.83 | 566,843 | |
| $45.61 | -0.12 | -0.3% | $45.81 | $46.14 | $44.99 | 597,690 | |
| $45.73 | -0.52 | -1.1% | $45.78 | $46.23 | $44.80 | 483,756 | |
| $46.25 | -1.52 | -3.2% | $45.27 | $47.36 | $44.64 | 499,637 | |
| $47.77 | -1.00 | -2.1% | $48.10 | $48.87 | $47.68 | 262,895 | |
| $48.77 | +0.39 | +0.8% | $49.00 | $49.12 | $47.81 | 230,746 | |
| $48.38 | +0.41 | +0.9% | $47.63 | $48.66 | $47.18 | 244,929 | |
| $47.97 | +1.52 | +3.3% | $47.03 | $48.96 | $46.19 | 323,838 | |
| $46.45 | +0.87 | +1.9% | $45.85 | $46.63 | $45.01 | 287,662 | |
| $45.58 | -1.93 | -4.1% | $47.51 | $47.74 | $45.47 | 380,689 | |
| $47.51 | -0.22 | -0.5% | $49.00 | $49.00 | $45.82 | 493,423 | |
| $47.73 | +0.82 | +1.7% | $47.36 | $48.35 | $47.36 | 304,495 | |
| $46.91 | -1.37 | -2.8% | $48.33 | $48.37 | $46.90 | 281,487 | |
| $48.28 | -0.36 | -0.7% | $48.45 | $48.97 | $47.89 | 293,615 | |
| $48.64 | -1.86 | -3.7% | $50.61 | $51.22 | $48.33 | 414,328 | |
| $50.50 | +0.87 | +1.8% | $49.76 | $50.55 | $49.00 | 306,131 | |
| $49.63 | +0.86 | +1.8% | $49.24 | $50.02 | $48.70 | 349,577 | |
| $48.77 | +0.04 | +0.1% | $48.97 | $49.62 | $47.98 | 417,135 | |
| $48.73 | +0.63 | +1.3% | $48.19 | $48.89 | $47.05 | 468,090 | |
| $48.10 | +0.16 | +0.3% | $47.65 | $48.51 | $46.83 | 254,904 | |
| $47.94 | +2.51 | +5.5% | $45.48 | $48.48 | $45.48 | 664,422 | |
| $45.43 | -3.81 | -7.7% | $49.57 | $51.85 | $44.02 | 1,201,785 | |
| $49.24 | +2.63 | +5.6% | $47.33 | $49.88 | $47.33 | 468,354 | |
| $46.61 | -2.10 | -4.3% | $48.56 | $48.56 | $46.46 | 413,600 | |
| $48.71 | +2.04 | +4.4% | $47.43 | $48.83 | $46.93 | 416,300 | |
| $46.67 | +1.08 | +2.4% | $45.25 | $47.24 | $45.00 | 494,100 | |
| $45.59 | -0.45 | -1.0% | $45.53 | $46.13 | $45.16 | 416,500 | |
| $46.04 | +0.09 | +0.2% | $46.16 | $46.78 | $45.99 | 371,600 | |
| $45.95 | -0.26 | -0.6% | $46.11 | $47.19 | $45.81 | 495,200 | |
| $46.21 | +0.56 | +1.2% | $45.36 | $46.77 | $44.74 | 554,200 | |
| $45.65 | -2.24 | -4.7% | $47.00 | $47.39 | $45.62 | 766,500 | |
| $47.89 | -1.31 | -2.7% | $49.41 | $49.41 | $47.35 | 627,100 | |
| $49.20 | +0.67 | +1.4% | $48.53 | $49.84 | $47.52 | 595,500 | |
| $48.53 | -0.10 | -0.2% | $48.97 | $49.83 | $48.28 | 441,100 | |
| $48.63 | -1.63 | -3.2% | $49.94 | $50.98 | $48.13 | 512,300 | |
| $50.26 | -0.11 | -0.2% | $50.13 | $52.02 | $49.39 | 1,430,100 | |
| $50.37 | -0.43 | -0.8% | $50.44 | $50.90 | $49.46 | 677,600 | |
| $50.80 | -0.20 | -0.4% | $51.00 | $51.65 | $50.50 | 412,600 | |
| $51.00 | -0.70 | -1.4% | $52.38 | $52.38 | $50.80 | 437,700 | |
| $51.70 | +0.93 | +1.8% | $50.59 | $52.16 | $50.35 | 417,800 | |
| $50.77 | -3.15 | -5.8% | $53.55 | $53.93 | $49.45 | 779,600 | |
| $53.92 | -1.00 | -1.8% | $55.07 | $56.04 | $50.61 | 755,700 | |
| $54.92 | -0.28 | -0.5% | $56.00 | $56.00 | $54.09 | 524,400 | |
| $55.20 | +0.14 | +0.3% | $55.76 | $55.77 | $53.71 | 868,800 | |
| $55.06 | +0.75 | +1.4% | $55.09 | $55.79 | $54.49 | 439,600 | |
| $54.31 | -0.37 | -0.7% | $54.44 | $54.80 | $53.62 | 394,100 | |
| $54.68 | +0.57 | +1.1% | $54.28 | $55.32 | $53.22 | 351,800 | |
| $54.11 | +0.24 | +0.4% | $54.58 | $55.70 | $54.00 | 436,800 | |
| $53.87 | -1.29 | -2.3% | $55.43 | $56.32 | $53.75 | 336,200 | |
| $55.16 | -0.54 | -1.0% | $55.43 | $56.43 | $54.31 | 300,100 | |
| $55.70 | -0.90 | -1.6% | $55.59 | $57.89 | $55.25 | 295,700 | |
| $56.60 | -0.20 | -0.4% | $55.48 | $58.17 | $54.79 | 1,036,100 | |
| $56.80 | -0.66 | -1.1% | $56.84 | $58.77 | $56.10 | 1,061,900 | |
| $57.46 | +1.62 | +2.9% | $56.33 | $57.77 | $55.00 | 363,800 | |
| $55.84 | +0.56 | +1.0% | $56.13 | $57.90 | $54.66 | 421,700 | |
| $55.28 | -1.75 | -3.1% | $56.82 | $58.09 | $54.84 | 773,900 | |
| $57.03 | +0.75 | +1.3% | $55.83 | $57.22 | $55.00 | 332,100 | |
| $56.28 | -1.01 | -1.8% | $57.24 | $57.24 | $55.38 | 358,300 | |
| $57.29 | -0.71 | -1.2% | $58.03 | $58.43 | $57.10 | 533,700 | |
| $58.00 | -0.37 | -0.6% | $58.27 | $58.86 | $57.37 | 210,300 | |
| $58.37 | -0.07 | -0.1% | $58.09 | $58.99 | $56.81 | 341,835 | |
| $58.44 | +0.70 | +1.2% | $56.96 | $59.07 | $55.57 | 627,045 | |
| $57.74 | +1.05 | +1.9% | $57.23 | $58.78 | $56.62 | 318,400 | |
| $56.69 | -2.57 | -4.3% | $58.52 | $59.69 | $56.33 | 389,300 |
Splits
1 split · NASDAQ:ANAB · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 3-for-2 | Split |
- Ticker
- NASDAQ:ANAB
- Asset type
- Stock
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 10 slides
Latest news
Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
Nov 12, 2026
Closed $46.25 (-3.2%) on Nov 13, 2026
Anaptys Announces Participation in Upcoming Investor Conferences
Nov 10, 2026
Closed $48.77 (+0.8%) on Nov 11, 2026
Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer
Oct 19, 2026
Closed $49.24 (+5.6%) on Oct 19, 2026
Annual Transition Report (Form 10-KT)
Sep 21, 2026
Closed $53.92 (-1.8%) on Sep 22, 2026
Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 1, 2026
Closed $55.84 (+1.0%) on Sep 2, 2026
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
Closed $62.69 (-4.4%) on May 13, 2026
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
May 11, 2026
Closed $67.92 (-2.0%) on May 11, 2026
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
May 4, 2026
Closed $69.28 (-0.7%) on May 5, 2026
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim
Apr 24, 2026
Closed $58.88 (+14.8%) on Apr 24, 2026
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
Apr 20, 2026
Closed $50.95 (+13.2%) on Apr 20, 2026
AnaptysBio, Inc. on 6ix
- News releases
- 19 in the last 12 months · 122 in all · newest Nov 12, 2026 · oldest 2019
- Decks
- 30 decks · latest September 2026
Where AnaptysBio, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ANAB · Home listing · This page | NASDAQ | United States | USD |
| gettex:AN6 | gettex | Germany | EUR |
| Lang & Schwarz:A2AJ8C | Lang & Schwarz | Germany | EUR |
| LS Exchange:A2AJ8C | LS Exchange | Germany | EUR |
| BMV:ANAB | BMV | Mexico | MXN |
| LSE:0HFQ | LSE | United Kingdom | USD |
| Tradegate:AN6 | Tradegate | Germany | EUR |
| BOATS:ANAB | BOATS | United States | USD |
| BIVA:ANAB | BIVA | Mexico | MXN |
| Frankfurt:AN6 | Frankfurt | Germany | EUR |
| Dusseldorf:AN6 | Dusseldorf | Germany | EUR |
| Munich:AN6 | Munich | Germany | EUR |
| Stuttgart:AN6 | Stuttgart | Germany | EUR |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.25B USD
- P/E
- 7.6×
- EV/sales
- 6.5×
- EV/EBITDA
- 6.2×
- Price/book
- 67.0×
- Gross margin
- 143.7%
- Operating margin
- 105.8%
- Net margin
- 96.3%
- Debt to equity
- 0.6×
- Beta vs S&P 500
- 0.95
Forecasts
5 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 87.25 USD · Analysts' mean
- EPS, year to Dec 2026
- 3.24 · 3 analysts
- Revenue, year to Dec 2026
- 136.7M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Dan Faga | President, CEO, and Director |
| Hollings Renton | Chair of the Nominating and Corporate Governance Committee |
| John Orwin | Board Chairman of First Tracks Bio Former CEO of Relypsa |
| Christopher Murphy | CFO |
| Nick Montemarano | Executive Director, Investor Relations |
Board
| Director | Role |
|---|---|
| John Orwin | Board Chairman of First Tracks Bio Former CEO of Relypsa |
| Dan Faga | President, CEO, and Director |
| Hollings Renton | Chair of the Nominating and Corporate Governance Committee |
| Nick Montemarano | Executive Director, Investor Relations |
| Oleg Nodelman | Member of the Nominating and Corporate Governance Committee |
| Owen Hughes | Member of the Audit Committee |
| Susannah Gray | Member of the Audit Committee |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | −3.2% |
| Q2 2026 | Sep 21, 2026 · After close | −1.8% |
| Q1 2026 | May 7, 2026 | +2.9% |
| Q4 2025 | Mar 3, 2026 · After close | +14.6% |
| Q3 2025 | Nov 4, 2025 · After close | +3.6% |
| Q2 2025 | Aug 6, 2025 · After close | −9.6% |
| Q1 2025 | May 5, 2025 · After close | −2.9% |
| Q4 2024 | Mar 10, 2025 · Before open | +2.4% |
| Q3 2024 | Nov 5, 2024 · After close | +11.7% |
| Q2 2024 | Aug 5, 2024 · After close | −0.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | −10.8% |
| Q4 2023 | Mar 11, 2024 · After close | +11.6% |
| Q3 2023 | Nov 2, 2023 · After close | +8.2% |
| Q2 2023 | Aug 7, 2023 · After close | +2.6% |
| Q1 2023 | May 11, 2023 · After close | −6.3% |
| Q4 2022 | Mar 1, 2023 · After close | −2.4% |
| Q3 2022 | Nov 8, 2022 · After close | −0.9% |
| Q2 2022 | Aug 8, 2022 · After close | −5.6% |
| Q1 2022 | May 4, 2022 · After close | −11.1% |
| Q4 2021 | Mar 7, 2022 · Before open | −0.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 10 slides | September 2026 |
| Investor Presentation (March 2026) | Investor deck | 66 slides | Mar 3, 2026 |
| Investor Presentation (January 2026) | Investor deck | 65 slides | Jan 9, 2026 |
| Investor Presentation (November 2025) | Investor deck | 67 slides | Nov 10, 2025 |
| Investor Day (October 2025) | Investor day | 56 slides | Oct 14, 2025 |
| Investor Presentation (October 2025) | Investor deck | 72 slides | Oct 14, 2025 |
| Merger or Acquisition (September 2025) | Merger or acquisition | 13 slides | Sep 29, 2025 |
| Investor Presentation (June 2025) | Investor deck | 55 slides | Jun 3, 2025 |
| Technical Presentation (June 2025) | Technical | 38 slides | Jun 3, 2025 |
| Investor Presentation (February 2025) | Investor deck | 45 slides | Feb 19, 2025 |
All 30 decks
IPO
Priced at US$15.00 a share on Jan 25, 2017.
- Price
- US$15.00 a share
- Shares offered
- 5,000,000 shares of common stock
- Offering size
- US$75 million
- Underwriters' option
- Up to 750,000 more shares
- Underwriters
- Credit Suisse, Stifel, JMP Securities, Wedbush PacGrow · In the order on the cover
- Shares delivered
- On or about Jan 31, 2017
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jul 17, 2015 |
| Filed publicly | Sep 9, 2015 |
| Amended 7 times | Newest Jan 17, 2017 |
| Shares registered with an exchange | Jan 17, 2017 |
| Declared effective by the SEC | Jan 25, 2017 |
| Final prospectus, with the price | Jan 26, 2017 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jan 26, 2017 |
| EFFECT · Notice that a registration is effective | Jan 25, 2017 |
| CERTNAS · Nasdaq's certificate of listing | Jan 24, 2017 |
| CORRESP · Letter to the SEC | Jan 23, 2017 |
| CORRESP · Letter to the SEC | Jan 23, 2017 |
| 8-A12B · Registration of shares for listing on an exchange | Jan 17, 2017 |
| S-1/A · Registration statement, amended | Jan 17, 2017 |
| CORRESP · Letter to the SEC | Jan 10, 2017 |
| CORRESP · Letter to the SEC | Dec 28, 2016 |
| S-1/A · Registration statement, amended | Dec 28, 2016 |
All 27 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Dec 1, 2016 |
| S-1/A · Registration statement, amended | Nov 15, 2016 |
| S-1/A · Registration statement, amended | Aug 19, 2016 |
| S-1/A · Registration statement, amended | May 10, 2016 |
| CORRESP · Letter to the SEC | Mar 22, 2016 |
| S-1/A · Registration statement, amended | Feb 16, 2016 |
| CORRESP · Letter to the SEC | Jan 11, 2016 |
| UPLOAD · Letter from the SEC | Jan 7, 2016 |
| S-1/A · Registration statement, amended | Dec 23, 2015 |
| CORRESP · Letter to the SEC | Sep 24, 2015 |
| CORRESP · Letter to the SEC | Sep 9, 2015 |
| S-1 · Registration statement | Sep 9, 2015 |
| UPLOAD · Letter from the SEC | Aug 31, 2015 |
| DRSLTR · Letter to the SEC with a draft | Aug 18, 2015 |
| DRS/A · Draft registration statement, amended | Aug 18, 2015 |
| UPLOAD · Letter from the SEC | Aug 14, 2015 |
| DRS · Draft registration statement | Jul 17, 2015 |
Open IPO · From the cover of the final prospectus (424B4) filed Jan 26, 2017
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 234.6M | 91.3M | 17.2M | 10.3M | 63.2M | 75.0M | 8.00M | 5.00M | 10.0M | 16.7M |
| Cost of revenue | 2.42M | 163.8M | 132.3M | 88.8M | 98.5M | 80.0M | 99.3M | 56.2M | 29.4M | 15.4M |
| Gross profit | 232.2M | -72.6M | -115.1M | -78.5M | -35.3M | -5.03M | -91.3M | -51.2M | -19.4M | 1.26M |
| Research and development | 136.0M | 163.8M | 132.3M | 88.8M | 98.5M | 80.0M | 99.3M | 56.2M | 29.4M | 15.4M |
| Selling, general and administrative | 50.7M | 42.4M | 41.9M | 36.6M | 21.5M | 18.9M | 16.1M | 15.5M | 9.34M | 4.29M |
| Operating income | 226.9M | 66.2M | -164.4M | -115.2M | -56.8M | -23.9M | -107.4M | -66.7M | -28.8M | -3.02M |
| Depreciation and amortization | 20.0K | 20.0K | 652.0K | 675.0K | 619.0K | 559.0K | 514.0K | 315.0K | 183.0K | 233.0K |
| EBITDA | 226.9M | 66.2M | -163.8M | -114.5M | -56.2M | -23.3M | -106.9M | -66.4M | -28.6M | -2.79M |
| Interest expense | 79.9M | 50.1M | 18.1M | 21.1M | 0 | 0 | 1.04M | 1.65M | 1.77M | 458.0K |
| Income before tax | 162.3M | 31.1M | -163.6M | -128.7M | -57.8M | -19.9M | -97.5M | -61.8M | -30.1M | -4.26M |
| Income tax | 772.0K | 158.0K | -4.00K | 24.0K | 0 | 0 | -152.0K | -192.0K | 0 | 0 |
| Net income | -13.2M | -145.2M | -163.6M | -128.7M | -57.8M | -19.9M | -97.3M | -61.7M | -30.1M | -4.26M |
| Earnings per share, basic | -0.46 | -5.12 | -6.08 | -4.57 | -2.11 | -0.73 | -3.60 | -2.50 | -1.52 | -1.62 |
| Earnings per share, diluted | -0.44 | -4.92 | -6.08 | -4.57 | -2.11 | -0.73 | -3.60 | -2.50 | -1.52 | -1.62 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 138.2M | 23.1M | 36.0M | 71.3M | 495.7M | 250.5M | 171.0M | 113.6M | 81.2M | 51.2M |
| Short-term investments | 73.4M | 262.3M | 354.9M | 369.9M | 52.4M | 143.2M | 203.2M | 313.5M | 167.2M | 0 |
| Receivables | 33.9M | 40.8M | 6.85M | 1.42M | 876.0K | 0 | 0 | 0 | 0 | 1.23M |
| Inventory | 1 | 1 | 1 | 0 | 1 | |||||
| Current assets | 350.3M | 431.9M | 406.8M | 447.2M | 553.9M | 396.6M | 377.7M | 434.2M | 252.7M | 58.2M |
| Property, plant and equipment | 111.0K | 131.0K | 2.10M | 2.09M | 2.28M | 1.78M | 1.62M | 1.45M | 665.0K | 471.0K |
| Goodwill | 0 | |||||||||
| Total assets | 364.4M | 483.8M | 452.4M | 610.4M | 643.1M | 416.6M | 435.2M | 509.0M | 329.4M | 62.2M |
| Accounts payable | 3.87M | 4.00M | 4.70M | 2.78M | 1.74M | 4.22M | 16.2M | 5.44M | 2.32M | 2.28M |
| Current liabilities | 38.6M | 45.4M | 37.4M | 26.1M | 16.1M | 19.8M | 29.5M | 21.8M | 14.1M | 5.71M |
| Long-term debt | 625.0K | 7.55M | 13.8M | |||||||
| Total debt | 14.1M | 369.5M | 17.8M | 19.4M | 21.0M | 342.0K | 2.90M | 8.26M | 14.4M | 13.8M |
| Total liabilities | 327.2M | 413.0M | 364.3M | 348.3M | 286.6M | 19.8M | 30.2M | 22.6M | 21.8M | 22.9M |
| Shareholders' equity | 37.2M | 70.9M | 88.1M | 262.1M | 356.4M | 396.7M | 405.0M | 486.4M | 307.6M | -38.2M |
| Shares outstanding | 28.0M | 30.5M | 26.6M | 28.5M | 27.6M | 27.4M | 27.3M | 26.9M | 23.8M | 2.65M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 19.7M | -135.3M | -120.8M | -73.6M | -45.9M | -14.2M | -69.5M | -48.5M | -19.4M | -9.03M |
| Capital spending | -87.0K | -358.0K | -807.0K | -358.0K | -1.37M | -569.0K | -805.0K | -1.06M | -290.0K | -50.0K |
| Free cash flow | 19.6M | -135.7M | -121.6M | -74.0M | -47.3M | -14.7M | -70.3M | -49.6M | -19.7M | -9.08M |
| Cash from investing | 228.0M | 31.4M | 144.8M | -394.8M | 38.8M | 94.5M | 131.4M | -142.5M | -243.1M | -50.0K |
| Cash from financing | -132.6M | 127.1M | -59.3M | 44.0M | 252.3M | -879.0K | -4.49M | 223.4M | 292.5M | 8.63M |
| Dividends paid | -11.7M | 0 | ||||||||
| Share buybacks | -68.6M | -456.0K | -50.0M | 0 | 0 | 496.0K | 3.01M | 0 | 0 | -1.00K |
| Change in cash | 115.1M | 23.1M | -35.3M | -424.4M | 245.2M | 79.4M | 57.4M | 32.4M | 30.0M | -452.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 18, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 1, 2026 | Other filings | SEC |
| 10-KT · Transition report | Sep 21, 2026 | Annual report | SEC |
| 8-K · Current report | Sep 21, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 17, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 11, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 30, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Jul 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 30, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
| ARS · Annual report to shareholders | Jun 29, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jun 29, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jun 29, 2026 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Jun 26, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 22, 2026 | Material contract | SEC |
| 144 · Notice of proposed sale | Jun 17, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 16, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 9, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 1, 2026 | Other filings | SEC |
| 8-K · Current report | May 29, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | May 29, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 28, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 27, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 26, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 22, 2026 | Other filings | SEC |
| 8-K · Current report | May 21, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | May 21, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 19, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | May 15, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 13, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| 8-K · Current report | May 11, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Apr 29, 2026 | Insider trade | SEC |
| 10-K/A · Annual report, amended | Apr 28, 2026 | Annual report | SEC |
| 8-K/A · Current report, amended | Apr 24, 2026 | Current report | SEC |
| 4/A · Change in ownership, amended | Apr 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 20, 2026 | Acquisition or disposal | SEC |
| 3 · Initial statement of ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 30, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 27, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 3, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 3, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 11, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 11, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 9, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 9, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 7, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 23, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 22, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 22, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 22, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 26, 2025 | Current report | SEC |
| 8-K · Current report | Nov 21, 2025 | Current report | SEC |
| 8-K · Current report | Nov 21, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 10, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 4, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2025 | Results | SEC |
| 8-K · Current report | Oct 14, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 1, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 30, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 29, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 23, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 8, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 7, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Aug 6, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 5, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 29, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 18, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 17, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 6, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 3, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 30, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 27, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 24, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 7, 2025 | Big-stake notice | SEC |
| 10-K · Annual report | Feb 27, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 27, 2025 | Results | SEC |
| 8-K · Current report | Feb 19, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 18, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 12, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 3, 2025 | Material contract | SEC |
| 4 · Change in ownership | Jan 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
This page holds 200 of 730 filings. Open Filings
Cap table
Built by 6ix from AnaptysBio, Inc.’s releases · as of Sep 21, 2026
- Common shares
- 29,895,244
- Fully diluted
- 29,895,244
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 29,895,244 | Sep 21, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Sep 21, 2026 | 29,895,244 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| James N Topper Other companies: Attovia Therapeutics, Inc. (Director · Since at least Aug 4, 2026); NewAmsterdam Pharma Company N.V. (Director · Since at least Dec 29, 2023); Phathom Pharmaceuticals, Inc. (Director · Since at least Oct 24, 2019); Frazier Lifesciences Acquisition Corp (Chief Executive Officer, Director · Dec 8, 2020 – Dec 11, 2020 · Past); Entasis Therapeutics Holdings Inc (Director · Sep 25, 2018 – Jan 18, 2019 · Past); Aptinyx Inc (Director · Jun 20, 2018 – Mar 31, 2020 · Past); Allena Pharmaceuticals Inc (Director · Nov 1, 2017 – Nov 17, 2020 · Past); Alpine Immune Sciences Inc (Director · Jul 24, 2017 – May 18, 2024 · Past); Sierra Oncology Inc (Director · Jul 15, 2015 – Feb 14, 2017 · Past); Portola Pharmaceuticals Inc (Director · May 21, 2013 – Jun 5, 2013 · Past); Amicus Therapeutics Inc (Director · Jun 15, 2010 – Jun 12, 2014 · Past) | Director · Jan 25, 2017 – Jan 6, 2023 · Past |
| John Schmid Other companies: BlossomHill Therapeutics, Inc. (Director · Since at least Aug 6, 2026); First Tracks Biotherapeutics, Inc. (Director · Since at least Apr 1, 2026); Helix Acquisition Corp. III (Director · Since at least Jan 22, 2026); Design Therapeutics, Inc. (Director · Since at least Mar 25, 2021); BridgeBio Oncology Therapeutics, Inc. (Director · Feb 8, 2024 – Feb 8, 2024 · Past); Xeris Biopharma Holdings, Inc. (Director · Oct 5, 2021 – Aug 12, 2024 · Past); MoonLake Immunotherapeutics (Director · Oct 19, 2020 – Oct 19, 2020 · Past); Poseida Therapeutics Inc (Director · Jul 9, 2020 – Jan 8, 2025 · Past); Neos Therapeutics Inc (Director · Jul 2, 2018 – Mar 19, 2021 · Past) | Director · Since at least Feb 2, 2018 |
| Hollings Renton Other companies: Zymeworks Inc. (Director · Jan 1, 2019 – Dec 7, 2023 · Past); Kythera Biopharmaceuticals Inc (Director · Dec 31, 2014 – Oct 1, 2015 · Past); Portola Pharmaceuticals Inc (Director · May 21, 2013 – Jul 2, 2020 · Past); Affymax Inc (Director · Jun 9, 2009 – Jun 13, 2012 · Past); Rigel Pharmaceuticals, Inc. (Director · May 31, 2006 – May 15, 2013 · Past); Cepheid (Director · Apr 27, 2006 – Nov 4, 2016 · Past); Onyx Pharmaceuticals Inc (President and CEO, Director · Jan 19, 2006 – Feb 19, 2008 · Past) | Chair of the Nominating and Corporate Governance Committee · Since at least Jan 25, 2017 |
| Oleg Nodelman Other companies: Theravance Biopharma, Inc. (BSFS · Since at least Nov 5, 2026); Aktis Oncology, Inc. (Director · Since at least Jan 8, 2026); Zymeworks Inc. (Director · Since at least Feb 17, 2025); Nuvation Bio Inc. (Director · Jun 30, 2020 – Sep 19, 2023 · Past); Panacea Acquisition II Corp (Director · Apr 6, 2020 – Apr 28, 2023 · Past); Prothena Corporation plc (Director · Dec 3, 2019 – Dec 3, 2019 · Past); Kindred Biosciences Inc (Director · Dec 11, 2013 – Sep 29, 2014 · Past) | Member of the Nominating and Corporate Governance Committee · Since at least Apr 8, 2021 |
| Owen Hughes Other companies: XOMA Royalty Corporation (Chief Executive Officer, Director · Since at least Nov 11, 2024); C4 Therapeutics, Inc. (Director · Since at least Nov 16, 2023); ImageneBio, Inc. (Director · Dec 14, 2022 – Jun 7, 2024 · Past); Pardes Biosciences Inc (Director · Feb 16, 2021 – Dec 23, 2021 · Past); Cullinan Therapeutics, Inc. (President and CEO, Director · Jan 7, 2021 – Jan 12, 2021 · Past); Translate Bio Inc (Director · Jun 27, 2018 – Sep 14, 2021 · Past); Radius Health, Inc. (Director · Apr 23, 2013 – Aug 15, 2022 · Past) | Member of the Audit Committee · Since at least May 11, 2026 |
| Dennis M Fenton Other companies: First Tracks Biotherapeutics, Inc. (Director · Since at least Apr 1, 2026); Portola Pharmaceuticals Inc (Director · Jun 17, 2016 – Jul 2, 2020 · Past); XenoPort Inc (Director · May 17, 2016 – Jul 5, 2016 · Past); Pfenex Inc (Director · May 6, 2016 – May 5, 2017 · Past) | Director · Since at least Mar 5, 2018 |
| Rita Jain Other companies: First Tracks Biotherapeutics, Inc. (Director · Since at least Apr 1, 2026); SAB Biotherapeutics, Inc. (Director · Since at least Jan 5, 2026); Avalo Therapeutics, Inc. (Director · Since at least Jun 17, 2025); Celldex Therapeutics, Inc. (Director · Since at least Jun 13, 2024) | Director · Since at least Jan 3, 2024 |
| Susannah Gray Other companies: Maravai LifeSciences Holdings, Inc. (Director · Since at least May 23, 2024); 4D Molecular Therapeutics, Inc. (Director · Since at least May 21, 2024); Theravance Biopharma, Inc. (Director · Since at least May 8, 2024); Morphic Holding Inc (Director · Jun 4, 2024 – Aug 16, 2024 · Past) | Director · Since at least Mar 26, 2026 |
| J Anthony Ware Other companies: First Tracks Biotherapeutics, Inc. (Director · Since at least Apr 1, 2026) | Director · Since at least Aug 22, 2017 |
| Nick Montemarano Other companies: First Tracks Biotherapeutics, Inc. (Vice President, Investor Relations · Since at least Nov 3, 2026) | Executive Director, Investor Relations · Since at least Mar 3, 2026 |
All 16 people
| Person | Seat |
|---|---|
| Christopher Murphy | CFO · Since at least May 11, 2026 |
| Dan Faga | President, CEO, and Director · Since at least Apr 24, 2026 |
| Eric J Loumeau | CHIEF LEGAL OFFICER · Since at least Sep 30, 2025 |
| John Orwin | Board Chairman of First Tracks Bio Former CEO of Relypsa · Since at least Sep 17, 2026 |
| Marco Londei | Chief Medical Officer · Jan 25, 2017 – Dec 6, 2019 · Past |
| Matthew Moyle | Chief Scientific Officer · Jan 25, 2017 – Feb 24, 2017 · Past |
Log in to ask 6ix AI your own questions about AnaptysBio, Inc.